The International Association for the Study of Lung Cancer (IASLC) has named Michael Boyer, MBBS, FRACP, PhD, as the 2021 recipient of the Adi F. Gazdar IASLC Merit Award. The announcement was made during the IASLC 2021 World Conference on Lung Cancer.
In 2019, the IASLC Board of Directors unanimously voted to elevate its recognition of Adi F. Gazdar, MD, to one of its highest honors by renaming the IASLC Merit Award for him. The award commemorates Dr. Gazdar’s lifelong dedication to lung cancer research through his pioneering work in molecular pathology. The recipient is chosen by the IASLC Executive Committee and is announced and recognized at the annual World Conference on Lung Cancer.
Michael Boyer, MBBS, FRACP, PhD
Adi F. Gazdar, MD
Dr. Boyer is Chief Clinical Officer for the Chris O’Brien Lifehouse, a not-for-profit comprehensive cancer center in Sydney, Australia. Previously, he served as Director of Cancer Services for the Sydney South West Area Health Service. He also has an appointment as Clinical Professor within the Central Clinical School of the University of Sydney. He is Co-Chair of Medical Oncology and Thoracic Oncology at Lifehouse.
In 2010, Dr. Boyer was made a member of the Order of Australia for his work as an educator, as a clinical trials researcher, and for his involvement in the development of integrated care facilities for people with cancer. Dr. Boyer continues to be actively involved in research, focusing on the testing of new anticancer drugs for the treatment of lung cancer. Dr. Boyer has a Bachelor of Medicine and Bachelor of Surgery from the University of Sydney and a doctorate in Cell Biology from the University of Toronto. He has been involved in the Lifehouse project from the beginning, alongside his friend and colleague Chris O’Brien, MD, and remains dedicated to helping guide the clinical direction of the facility.
“I see my role at Lifehouse as an amazing opportunity to help those with cancer and their families, while at the same time working on research that will eliminate cancer as a problem,” said Dr. Boyer.
